Abstract
Gastric and gastro-oesophageal cancers represent a global health problem. In recent years, there has been a marked increase in the incidence of proximal gastric and distal oesophageal adenocarcinomas. Surgery is the primary therapy for localised gastric or gastro-oesophageal cancer; however, patients treated with surgery have high rates of local and distant relapse as well as an unacceptably low 5-year survival rate. Chemoradiation and preoperative chemotherapy can play an important role for these patients. The outcome of patients with metastatic disease is very poor but a number of newer chemotherapy agents, such as docetaxel, oxaliplatin and S-1, have been identified and some have shown promising results. This article reviews recent trials on localised and metastatic gastric and gastro-oesophageal cancers.
Original language | English (US) |
---|---|
Pages (from-to) | 2805-2812 |
Number of pages | 8 |
Journal | Expert opinion on pharmacotherapy |
Volume | 6 |
Issue number | 16 |
DOIs | |
State | Published - Dec 2005 |
Keywords
- Adjuvant therapy
- Chemotherapy
- Gastric cancer
- Gastro-oesophageal cancer
- Neoadjuvant therapy
- Radiotherapy
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)